How big is Tango Therapeutics, Inc.?

As of Jun 18, Tango Therapeutics, Inc. has a market capitalization of 520.83 million, with net sales of 41.00 million and a net profit of -132.27 million over the latest four quarters. As of Dec'24, shareholder's funds were 199.52 million, and total assets were 328.94 million.

Market Cap: As of Jun 18, Tango Therapeutics, Inc. has a market capitalization of 520.83 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Tango Therapeutics, Inc. reported net sales of 41.00 million and a net profit of -132.27 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company's shareholder's funds amounted to 199.52 million, while total assets were reported at 328.94 million.

What does Tango Therapeutics, Inc. do?

Tango Therapeutics, Inc. is a micro-cap biotechnology company focused on pharmaceuticals, with recent net sales of $5 million and a net loss of $40 million. It has a market cap of $520.83 million and key metrics indicating significant financial challenges.

Overview:<BR>Tango Therapeutics, Inc. is a company in the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap entity.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 5 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -40 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 520.83 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.29 <BR>Return on Equity: -79.32% <BR>Price to Book: 3.12<BR><BR>Contact Details:<BR>Address: 11682 El Camino Real, Suite 320, SAN DIEGO CA: 92130 <BR>Tel: 1 858 4003115 <BR>Fax: 1 561 6941639

Should I buy, sell or hold Tango Therapeutics, Inc.?

Is Tango Therapeutics, Inc. overvalued or undervalued?

As of August 9, 2021, Tango Therapeutics, Inc. is considered risky and overvalued due to negative financial metrics, including a high Price to Book Value of 2.77, an EV to Sales ratio of 6.04, a troubling ROE of -79.32%, and a less efficient EV to EBITDA ratio compared to peers, despite a strong year-to-date stock return of 154.69%.

As of 9 August 2021, the valuation grade for Tango Therapeutics, Inc. changed from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its negative financial metrics, including a Price to Book Value of 2.77 and an EV to Sales ratio of 6.04, which suggest that investors are paying a premium despite the company's losses. Additionally, the ROE stands at a concerning -79.32%, further underscoring the company's challenges.<BR><BR>In comparison to its peers, Tango Therapeutics has a significantly higher EV to EBITDA ratio of -1.73 compared to Vir Biotechnology, Inc. at -0.0645 and Xencor, Inc. at -2.2827, indicating that it is less efficient in generating earnings before interest, taxes, depreciation, and amortization. Despite a strong year-to-date stock return of 154.69%, which outperformed the S&P 500's 12.22%, the overall negative returns over one year (-4.95%) and five years (-22.46%) suggest that the stock's recent performance may not be sustainable, reinforcing the notion that it is overvalued.

Is Tango Therapeutics, Inc. technically bullish or bearish?

As of October 31, 2025, Tango Therapeutics, Inc. shows a bullish technical trend with strong daily moving averages and a year-to-date return of 159.22%, despite mixed MACD signals and underperformance over longer periods compared to the S&P 500.

As of 31 October 2025, the technical trend for Tango Therapeutics, Inc. has changed from mildly bullish to bullish. The daily moving averages indicate a bullish stance, while the weekly MACD is mildly bearish, and the monthly MACD is mildly bullish. Bollinger Bands show a mildly bullish trend in both weekly and monthly time frames. <BR><BR>Despite the mixed signals from MACD and KST, the overall technical stance is bullish, supported by the daily moving averages. The company has shown strong returns, with a year-to-date return of 159.22% compared to the S&P 500's 16.30%, and a one-year return of 55.53% against the S&P 500's 19.89%. However, over longer periods, such as three years and five years, the stock has underperformed relative to the benchmark.